- Developing a three-dimensional vascularized tumor organoid culture platform “Tumor-On–VascularNet” with stable blood and nutrient transportation to predict chemoimmunotherapy efficacy in esophageal adenocarcinoma (EAC) patients. 
- Reconstituting tumor microenvironment in vitro with engineered human vascular endothelial cells (R-VECs) and immune cells (macrophages, neutrophils, etc.) to investigate therapy resistance and epigenetic reprogramming within tumor organoids and tumor-associated cells.
- Identifying novel therapeutic targets or biomarkers to improve chemoimmunotherapy efficacy with angiogenesis facilitated tumor organoid culture.
- Developing a three-dimensional semi-physiological culture platform to expand human reproductive tissues in vitro, including spermatogonial stem and progenitor cells (SSCs), testicular seminiferous tubules, normal prostate or prostate cancer (PCa) organoids.